Guidant COMPANION Results Support Contak CD Mortality Benefit
This article was originally published in The Gray Sheet
Executive Summary
Guidant's Contak CD cardiac resynchronization therapy pacemaker/ICD demonstrated a 40% reduction in all-cause mortality compared with optimum medical therapy, data from the firm-sponsored COMPANION study show